AbbVie (ABBV) has turned investor attention with its steady performance, despite the overall market dip. Renowned investor Louis Navellier holds it among his top long-term stock picks. The company recently acquired
Nimble Therapeutics, aiming to bolster its immunology pipeline, while keeping its hold on the Humira market. Anticipation of top-line growth from its immunosuppressive drugs and advancement in its solid tumor pipeline are other noteworthy endeavors. AbbVie also looks forward, currently developing a groundbreaking gene therapy for vision loss treatment in collaboration with REGENXBIO, and seeking to strengthen focus in Alzheimer's disease and neuroscience through the acquisition of
Aliada Therapeutics. Despite reporting a $3.5 billion impairment charge for a failed schizophrenia drug, the company assures immense cash flow potential and a healthy balance sheet. Its massive cash flow opportunity and robust dividends make
ABBV a clear favorite, specifically for dividend growth investors. However, recent impact from recent acquisitions invites investors to keep an eye on potential outcomes.
Abbvie ABBV News Analytics from Thu, 13 Jun 2024 07:00:00 GMT to Sat, 18 Jan 2025 17:05:10 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor -3
